Chinese biosimilars developer Bio-Thera Solutions has announced plans to develop “novel oral monoclonal antibody treatments for chronic gastrointestinal inflammatory diseases,” after striking a deal with Intract Pharma that will give it access to its Soteria and Phloral drug-delivery technologies.
According to Bio-Thera, the “global collaboration and license agreement” with Intract will see Bio-Thera granted a “worldwide license to Intract’s oral biologics drug
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?